Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
about
Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much?Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.Molecular biomarkers: a US FDA effort.The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients.Use of diagnostic accuracy as a metric for evaluating laboratory proficiency with microarray assays using mixed-tissue RNA reference samples.Qualification of biomarkers for drug development in organ transplantation.
P2860
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@ast
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@en
type
label
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@ast
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@en
prefLabel
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@ast
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@en
P356
P1476
Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
@en
P2093
Federico Goodsaid
Felix W Frueh
P304
P356
10.1002/EM.20294
P577
2007-06-01T00:00:00Z